December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Nico Gagelmann: Suggesting Bispecific Antibodies as Standard of Care for Relapse After CAR-T in Multiple Myeloma
Dec 8, 2024, 06:51

Nico Gagelmann: Suggesting Bispecific Antibodies as Standard of Care for Relapse After CAR-T in Multiple Myeloma

Nico Gagelmann, Co-chair of EBMT’s Trainee Committee, shared a recent article on X:

“Finally out and timely for ASH24 The American Society of Hematology (ASH).

Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple myeloma mmsm.”

Title: Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

Authors: Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al-Ola Abdallah and Nico Gagelmann

 Nico Gagelmann

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, also reshared the post:

Congratulations to both Nico Gagelmann and Maximilian Merz for publishing Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy great International effort.”

Nico Gagelmann is a physician and scientist who co-founded and co-chairs the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee, and he also serves as the chair of the EBMT subcommittee focused on CAR-T cell therapies for plasma cell disorders. His work is particularly impactful in the realm of CAR-T treatments for multiple myeloma, where he has contributed to advancing research and clinical approaches.

More posts featuring Nico Gagelmann.